Literature DB >> 33388617

Assessing skeletal muscle mass based on the cross-sectional area of muscles at the 12th thoracic vertebra level on computed tomography in patients with oral squamous cell carcinoma.

Remi Matsuyama1, Keisuke Maeda2, Yosuke Yamanaka1, Yuria Ishida3, Ryoko Kato4, Tomoyuki Nonogaki4, Akio Shimizu5, Junko Ueshima6, Yoshiaki Kazaoka1, Tomio Hayashi1, Kunihiro Ito1, Akifumi Furuhashi1, Takayuki Ono1, Naoharu Mori7.   

Abstract

OBJECTIVES: This study aimed to create a formula to estimate the third lumbar vertebra (L3)1 level skeletal muscle cross-sectional area (CSA), known as a standard value to evaluate skeletal muscle mass on computed tomography (CT), using the twelfth thoracic vertebra (Th12) level skeletal muscle CSA on chest CT.
MATERIALS AND METHODS: This retrospective observational study included patients aged 40 + years with a diagnosis of oral squamous cell carcinoma (n = 164). Skeletal muscle CSA on CT images was measured using the Th12 and the L3 levels of pretreatment CT scans. The predictive formula was created based on the five-fold cross-validation method with a linear regression model. Correlations between the predicted L3-level CSA and the actual L3-level CSA were evaluated using r and Intraclass Correlation Coefficients (ICC).
RESULTS: The predictive formula for L3-level CSA from Th12-level CSA was: CSA at L3 (cm2) = 14.143 + 0.779 * CSA at Th12 (cm2) - 0.212 * Age (y) + 0.502 * Weight (kg) + 13.763 * Sex. Correlations between the predicted and measured L3-level CSA were r = 0.915 [0.886-0.937] and ICC = 0.911 [0.881-0.934].
CONCLUSION: We developed a formula for predicting skeletal muscle mass from the Th12-level CT slice. The predicted L3-level CSA correlated with the measured L3-level CSA.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Estimation formula; Head and neck tumor; Oral cancer; Sarcopenia; Skeletal muscle mass

Year:  2020        PMID: 33388617     DOI: 10.1016/j.oraloncology.2020.105126

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  2 in total

1.  Sarcopenia at the infrahyoid level as a prognostic factor in patients with advanced-stage non-virus-related head and neck carcinoma.

Authors:  Daisuke Yunaiyama; Mitsuru Okubo; Eri Arizono; Kiyoaki Tsukahara; Maki Tanigawa; Toshitaka Nagao; Kazuhiro Saito
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-10-25       Impact factor: 2.503

Review 2.  Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty.

Authors:  Remco de Bree; Christiaan D A Meerkerk; Gyorgy B Halmos; Antti A Mäkitie; Akihiro Homma; Juan P Rodrigo; Fernando López; Robert P Takes; Jan B Vermorken; Alfio Ferlito
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.